JOP20230077A1 - محفزات glp 1/ gip مزدوجة - Google Patents

محفزات glp 1/ gip مزدوجة

Info

Publication number
JOP20230077A1
JOP20230077A1 JOJO/P/2023/0077A JOP20230077A JOP20230077A1 JO P20230077 A1 JOP20230077 A1 JO P20230077A1 JO P20230077 A JOP20230077 A JO P20230077A JO P20230077 A1 JOP20230077 A1 JO P20230077A1
Authority
JO
Jordan
Prior art keywords
gip
stimulators
dual glp
obesity
diabetes
Prior art date
Application number
JOJO/P/2023/0077A
Other languages
English (en)
Inventor
Vinod Sampatrao Burade
Abhishek Tiwari
Rajamannar Thennati
Dhiren Rameshchandra Joshi
Chandulal Thakarshibhai Jivani
Krunal Harishbhai Soni
Manish Harendraprasad Gandhi
Muthukumaran Natarajan
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of JOP20230077A1 publication Critical patent/JOP20230077A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Evolutionary Computation (AREA)
  • Computing Systems (AREA)

Abstract

يتعلق الاختراع الحالي ببولي ببتيد مساعد مزدوج وممتد المفعول مكون من ببتيد شبيه بالجلوكاجون-1 وبولي ببتيد مفرز للإنسولين اعتمادًا على الجلوكوز البشري (GIP) والذي يفيد في علاج النوع 2 من البول السكري (T2D)، والسكري الناتج عن السِمنة، والسِمنة وفرط الدهون في الدم.
JOJO/P/2023/0077A 2020-10-17 2023-04-16 محفزات glp 1/ gip مزدوجة JOP20230077A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202021045240 2020-10-17
IN202121002837 2021-01-20
PCT/IB2021/059420 WO2022079639A1 (en) 2020-10-17 2021-10-13 Glp-1/gip dual agonists

Publications (1)

Publication Number Publication Date
JOP20230077A1 true JOP20230077A1 (ar) 2023-04-16

Family

ID=78302859

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0077A JOP20230077A1 (ar) 2020-10-17 2023-04-16 محفزات glp 1/ gip مزدوجة

Country Status (16)

Country Link
US (2) US20240020543A1 (ar)
EP (1) EP4204440A1 (ar)
JP (1) JP7830441B2 (ar)
KR (1) KR20230088337A (ar)
CN (1) CN116171164A (ar)
AU (1) AU2021361263A1 (ar)
BR (1) BR112023003668A2 (ar)
CA (1) CA3195155A1 (ar)
CL (1) CL2023000960A1 (ar)
CO (1) CO2023001960A2 (ar)
IL (1) IL301109A (ar)
JO (1) JOP20230077A1 (ar)
MX (1) MX2023002906A (ar)
PE (1) PE20231309A1 (ar)
TW (1) TW202229323A (ar)
WO (1) WO2022079639A1 (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023003668A2 (pt) 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
IL308392A (en) 2021-05-13 2024-01-01 Carmot Therapeutics Inc G protein-coupled receptor modulators
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
IL318349A (en) * 2022-07-13 2025-03-01 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Glp-1/gip dual agonist, preparation method and use thereof
CA3262093A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical Formulations and Methods for the Treatment of Metabolic and Liver Disorders
CN117756913B (zh) * 2022-11-07 2025-05-09 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法
KR20250124883A (ko) * 2022-12-21 2025-08-20 베링거 인겔하임 인터내셔날 게엠베하 Glp1/gip/npy2 수용체 삼중 작용제
WO2024152259A1 (zh) * 2023-01-18 2024-07-25 上海民为生物技术有限公司 具有三重活性的融合蛋白及其应用
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2024243243A1 (en) * 2023-05-21 2024-11-28 Carmot Therapeutics Inc. Treatment of adults with overweight or obesity with or without weight-related comorbidities
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025163615A1 (en) 2024-01-31 2025-08-07 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1999259B1 (en) 2006-03-03 2014-06-25 California Institute of Technology Site-specific incorporation of amino acids into molecules
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
NZ702333A (en) * 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
US9340600B2 (en) * 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
KR102781241B1 (ko) 2017-01-17 2025-03-14 암젠 인크 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
UA128210C2 (uk) 2018-04-05 2024-05-08 Сан Фармасьютікал Індастріз Лімітед Аналог glp-1
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
TWI735917B (zh) 2018-07-23 2021-08-11 美商美國禮來大藥廠 Gip/glp1共促效劑化合物
AU2019309798A1 (en) * 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
WO2020207477A1 (zh) 2019-04-11 2020-10-15 江苏豪森药业集团有限公司 Glp-1和gip受体双重激动剂化合物及其应用
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
BR112023003668A2 (pt) 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip

Also Published As

Publication number Publication date
BR112023003668A2 (pt) 2023-04-25
AU2021361263A1 (en) 2023-02-16
IL301109A (en) 2023-05-01
KR20230088337A (ko) 2023-06-19
MX2023002906A (es) 2023-04-05
JP7830441B2 (ja) 2026-03-16
CO2023001960A2 (es) 2023-05-08
CN116171164A (zh) 2023-05-26
CA3195155A1 (en) 2022-04-21
CL2023000960A1 (es) 2023-11-10
US12622948B2 (en) 2026-05-12
JP2023545662A (ja) 2023-10-31
TW202229323A (zh) 2022-08-01
US20240020543A1 (en) 2024-01-18
US20240400613A1 (en) 2024-12-05
EP4204440A1 (en) 2023-07-05
PE20231309A1 (es) 2023-08-24
WO2022079639A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
MX2023002906A (es) Agonistas duales glp-1/gip.
JOP20220344A1 (ar) عوامل مساعدة glp-1/gip مزدوجة ممتدة المفعول
ZA202106369B (en) Gip/glp1 co-agonist compounds
MX2021005835A (es) Compuestos co-agonistas de gip y glp-1.
MY205796A (en) Gipr-agonist compounds
MX2021015328A (es) Agonistas del receptor del peptido-1 similar al glucagon.
WO2010054326A3 (en) C-terminal fragments of glucagon-like peptide-1 (glp-1)
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
AU2019378845A8 (en) Combination treatment of NAFLD and NASH
MX2023014740A (es) Tratamiento de la obesidad y trastornos relacionados con la obesidad.
MX2026000195A (es) Triagonista de los receptores glp-1, gip y gcg y su uso
ECSP23019850A (es) Agonistas duales glp-1/gip
TW202620037A (zh) Ｇｉｐ／ｇｌｐ１共促效劑化合物
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
TH2101000319A (th) สารประกอบอะโกนิสท์ร่วม gip/glp1